Cargando…

Advances in the diagnosis, evaluation, and management of leptomeningeal disease

Leptomeningeal metastasis (LM) is a devastating complication of cancer with variable clinical presentation and limited benefit from existing treatment options. In this review, we discuss advances in LM diagnostics and therapeutics with the potential to reverse this grim course. Emerging cerebrospina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sener, Ugur, Kumthekar, Priya, Boire, Adrienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633748/ https://www.ncbi.nlm.nih.gov/pubmed/34859236 http://dx.doi.org/10.1093/noajnl/vdab108

Ejemplares similares

ETMM-03. CANCER CELLS DEPLOY LIPOCALIN- 2 TO COLLECT LIMITING IRON IN LEPTOMENINGEAL METASTASIS
por: Chi, Yudan, et al.
Publicado: (2021)

SPCR-02 NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS TREATED WITH PROTON CRANIOSPINAL IRRADIATION
por: Correa, Denise, et al.
Publicado: (2022)

Leptomeningeal metastatic cells adopt two phenotypic states
por: Remsik, Jan, et al.
Publicado: (2020)

Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
por: Wilcox, Jessica A., et al.
Publicado: (2022)

Leptomeningeal Metastases: New Opportunities in the Modern Era
por: Wilcox, Jessica A., et al.
Publicado: (2022)

23. RETROSPECTIVE REVIEW OF ADULT PATIENTS WITH LEPTOMENINGEAL DISEASE SECONDARY TO MELANOMA AT MOFFITT CANCER CENTER: DIAGNOSIS, TREATMENT AND OUTCOMES
por: Pina, Yolanda, et al.
Publicado: (2020)

BSLD-06 UNVEILING THE RE-PROGRAMMING OF CHOROID PLEXUS AND LEPTOMENINGEAL METASTASIS
por: Nobre, Ana Rita, et al.
Publicado: (2023)

NEIM-01 INCIDENCE AND DIAGNOSTIC TECHNIQUES FOR LEPTOMENINGEAL DISEASE IN PATIENTS WITH BRAIN METASTASIS
por: Henry, Katie, et al.
Publicado: (2022)

LMD-10. The role of immune checkpoint inhibitors in leptomeningeal disease: a systematic review
por: Palmisciano, Paolo, et al.
Publicado: (2021)

LMD-21. Headache Improvement Predicts Survival after CSF diversion in Leptomeningeal Disease
por: Robin, Adam, et al.
Publicado: (2021)

Histone-mutant glioma presenting as diffuse leptomeningeal disease
por: Nadkarni, Tanvi, et al.
Publicado: (2021)

41. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS
por: Le Rhun, Emilie, et al.
Publicado: (2020)

Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer
por: Malani, Rachna, et al.
Publicado: (2020)

OMRT-15. Multidisciplinary management of non-small cell lung cancer patients with leptomeningeal metastasis in the TKI era
por: Chen, Kuan-Yu, et al.
Publicado: (2021)

LMD-19. Anatomic and Surgical Factors Predict Development of Leptomeningeal Disease in Patients with Metastatic Melanoma
por: Lowe, Stephen, et al.
Publicado: (2021)

11. ASSOCIATION OF TUMOR EXPOSURE TO CEREBROSPINAL FLUID SPACES TO LEPTOMENINGEAL DISEASE IN PATIENTS WITH BRAIN METASTASES
por: Patel, Kunal, et al.
Publicado: (2020)

RADI-08. Elucidating the Electrophysiology of Intraoperative Radiotherapy – Experience from Two Cases
por: Sener, Ugur, et al.
Publicado: (2021)

LMD-18. Detection and serial monitoring of CSF ctDNA in breast cancer leptomeningeal disease (BCLM)
por: Fitzpatrick, Amanda, et al.
Publicado: (2021)

LMD-09. Outcomes and symptom benefit from palliative radiotherapy for leptomeningeal disease in breast cancer patients
por: Takayesu, Jamie, et al.
Publicado: (2021)

Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD)
por: Ferguson, Sherise D., et al.
Publicado: (2022)

40. AN UPDATE ON THE DEVELOPMENT OF A NEW TOOL TO ASSESS RESPONSE IN LEPTOMENINGEAL METASTASIS
por: Weller, Michael, et al.
Publicado: (2020)

LMD-12. Ubiquitin Conjugating Enzymes promote leptomeningeal dissemination and decrease survival in patients with brain metastatic disease
por: Paisana, Eunice, et al.
Publicado: (2021)

Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report
por: Webb, Mason J, et al.
Publicado: (2023)

LMD-22. Clinicopathological spectrum of leptomeningeal metastases: A 3 year retrospective study
por: Pahwa, Saloni, et al.
Publicado: (2021)

OTME-17. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases
por: Smalley, Inna, et al.
Publicado: (2021)

21. A PHASE II TRIAL OF COMPREHENSIVE TREATMENT BASED ON RADIOTHERAPY IN LEPTOMENINGEAL METASTASIS
por: Yang, Siran, et al.
Publicado: (2020)

LOCL-06 SUPERVISED MACHINE LEARNING IDENTIFIES RISK FACTORS ASSOCIATED WITH LEPTOMENINGEAL DISEASE AFTER SURGICAL RESECTION OF BRAIN METASTASES
por: Morshed, Ramin, et al.
Publicado: (2022)

LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
por: Bander, Evan D, et al.
Publicado: (2021)

56. TUMOR-HOMING STEM CELL THERAPY INHIBITS THE PROGRESSION OF BREAST CANCER LEPTOMENINGEAL CARCINOMATOSIS
por: Jiang, Wulin, et al.
Publicado: (2020)

BSCI-08 NEURONAL MIMICRY PROMOTES BREAST CANCER LEPTOMENINGEAL METASTASIS FROM BONE MARROW
por: Whiteley, Andrew, et al.
Publicado: (2022)

LMD-20. Immune Suppressive Macrophages and Signal Transducer and Activator of Transcription 3 (STAT3) Expression are common in Melanoma Leptomeningeal Disease
por: Najem, Hinda, et al.
Publicado: (2021)

LMD-05. Phase 1B Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD): Preliminary Results
por: Pina, Yolanda, et al.
Publicado: (2021)

LMD-14. Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome ((186)RNL) for leptomeningeal metastases
por: Guerra-Garcia, Maria, et al.
Publicado: (2021)

LMD-04. FLAIR hyperintensity along the brainstem surface in leptomeningeal metastases: a case series and literature review
por: Mitsuya, Koichi, et al.
Publicado: (2021)

Asthma Management Guidelines: Updates, Advances, and New Options
por: Navarro, Robert P., et al.
Publicado: (2007)

Early Detection of Leptomeningeal Metastases Among Patients Undergoing Spinal Stereotactic Radiosurgery
por: Freret, Morgan E., et al.
Publicado: (2022)

BSLD-05 ESTABLISHMENT AND CHARACTERIZATION OF MOUSE MODELS OF LEPTOMENINGEAL METASTASIS
por: Derderian, Camille, et al.
Publicado: (2023)

58. CLINICAL PRESENTATION AND IMAGING CHARACTERISTICS OF LEPTOMENINGEAL CARCINOMATOSIS (LC) IN PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)
por: Eastman, Boryana, et al.
Publicado: (2020)

LMD-13. ReSPECT-LM: Maximum tolerated dose, safety, and efficacy of intraventricular Rhenium-186 Nanoliposome ((186)RNL) for leptomeningeal metastases
por: Brenner, Andrew, et al.
Publicado: (2021)

Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series
por: Sener, Ugur, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_adsv8n9rortg4cmm725eg96g1r